Therapeutic effect of yttrium oxide nanoparticles for the treatment of fulminant hepatic failure

• Published in: Nanomedicine (London, England) Vol. 14; no. 19; pp. 2519 - 2533
• Main Authors: Song, Xiang, Shang, Pan, Sun, Zhenwei, Lu, Mingzi, You, Guoxing, Yan, Shaoduo, Chen, Gan, Zhou, Hong
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.10.2019
• Subjects: Antioxidants; Apoptosis; Cell culture; cerium oxide nanoparticles; Cerium oxides; Cytotoxicity; D-galactosamine; Enzymes; Experiments; Free radicals; fulminant hepatic failure; Inflammation; Laboratory animals; lipopolysaccharide; Liver; Medical prognosis; Microscopy; Nanomaterials; Nanoparticles; Neutrophils; NF-κB activation; Oxidative stress; Pathogenesis; Reactive oxygen species; yttrium oxide nanoparticles; Beijing China; United States > US; China; Germany; cerium oxide nanoparticles; D-galactosamine; inflammation; fulminant hepatic failure; reactive oxygen species; NF-κB activation; lipopolysaccharide; yttrium oxide nanoparticles
• ISSN: 1743-5889; 1748-6963; 1748-6963
• DOI: 10.2217/nnm-2019-0154

To explore the potential therapeutic effect of yttrium oxide nanoparticles (Y O NPs) on fulminant hepatic failure. RAW264.7 cells and a lipopolysaccharide/D-galactosamine-induced hepatic failure murine model were used to assess the effects of Y O  NPs. Y O NPs exhibited anti-inflammatory activity by scavenging cellular reactive oxygen species and dampening reactive oxygen species-mediated NF-κB activation . A single intraperitoneal administration of Y O NPs (30 mg/kg) enhanced hepatic antioxidant status and reduced oxidative stress and inflammatory response in lipopolysaccharide/galactosamine-induced mice. Y O NPs also attenuated hepatic NF-κB activation, cell apoptosis and liver injury. Y O NP administration could be used as a novel therapeutic strategy for treating fulminant hepatic failure and oxidative stress-related diseases.